PDCD1 and esophageal cancer: Among the top 10 authors by publication volume, 7 are from Japan, 2 from the United States, and 1 from China, indicating Japan’s leadership in esophageal cancer immunotherapy research, especially in clinical trials (such as the application of anti-PD-1/PD-L1 antibodies).